Organic Process Research & Development最新文献

筛选
英文 中文
Kilo-Scale-Enabled Route toward PF-07907063, a Type II Brain Penetrant cMET Inhibitor 一种II型脑渗透cMET抑制剂PF-07907063的kilo - scale激活途径
IF 3.4 3区 化学
Organic Process Research & Development Pub Date : 2025-04-07 DOI: 10.1021/acs.oprd.4c00441
Grace McKenna, Cole Cruz, Bryon Simmons, James T. Brewster, II, Anna M. Benz-Weeden, Thomas A. Brandt, Quinn A. Bumpers, Adam Cook, Mohamed Saad Abdullah Elsayed, Daniel Golec, Nicholas Lewandowski, Phong Nguyen, Robert W. Pipal, Pavel Savechenkov, Christina E. Wong, Eugene Tarlton, John J. Gaudino, Ronald J. Hinklin, Tony P. Tang
{"title":"Kilo-Scale-Enabled Route toward PF-07907063, a Type II Brain Penetrant cMET Inhibitor","authors":"Grace McKenna, Cole Cruz, Bryon Simmons, James T. Brewster, II, Anna M. Benz-Weeden, Thomas A. Brandt, Quinn A. Bumpers, Adam Cook, Mohamed Saad Abdullah Elsayed, Daniel Golec, Nicholas Lewandowski, Phong Nguyen, Robert W. Pipal, Pavel Savechenkov, Christina E. Wong, Eugene Tarlton, John J. Gaudino, Ronald J. Hinklin, Tony P. Tang","doi":"10.1021/acs.oprd.4c00441","DOIUrl":"https://doi.org/10.1021/acs.oprd.4c00441","url":null,"abstract":"New synthetic methodologies that access complex saturated building blocks enable the synthesis of drug molecules with unique properties. Here, we report collaborative efforts between Pfizer’s Medicinal Chemistry, Medicinal Chemistry Synthesis Development, and Pharmaceutical Sciences Small Molecule (PSSM) groups for the development of kilogram-scale-enabled synthesis of a type II brain penetrant cMET inhibitor, PF-07907063. The chemistry presented herein demonstrates the importance of implementing a green chemistry approach for developing and applying new transformations throughout the drug development pipeline. Specifically, synthetic planning rooted in the 12 Principles of Green Chemistry led to advancements in deoxygenative photoredox-nickel dual catalysis and cross-electrophile nickel catalysis. The final route significantly lowered the process mass intensity (PMI), increased the yield of the final API, and allowed for the purification of key intermediates through crystallization versus purging impurities via column chromatography, among other improvements.","PeriodicalId":55,"journal":{"name":"Organic Process Research & Development","volume":"168 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143798411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kilo-Scale-Enabled Route toward PF-07907063, a Type II Brain Penetrant cMET Inhibitor 一种II型脑渗透cMET抑制剂PF-07907063的kilo - scale激活途径
IF 3.1 3区 化学
Organic Process Research & Development Pub Date : 2025-04-07 DOI: 10.1021/acs.oprd.4c0044110.1021/acs.oprd.4c00441
Grace McKenna, Cole Cruz, Bryon Simmons*, James T. Brewster II*, Anna M. Benz-Weeden, Thomas A. Brandt, Quinn A. Bumpers, Adam Cook, Mohamed Saad Abdullah Elsayed, Daniel Golec, Nicholas Lewandowski, Phong Nguyen, Robert W. Pipal, Pavel Savechenkov, Christina E. Wong, Eugene Tarlton, John J. Gaudino, Ronald J. Hinklin* and Tony P. Tang, 
{"title":"Kilo-Scale-Enabled Route toward PF-07907063, a Type II Brain Penetrant cMET Inhibitor","authors":"Grace McKenna,&nbsp;Cole Cruz,&nbsp;Bryon Simmons*,&nbsp;James T. Brewster II*,&nbsp;Anna M. Benz-Weeden,&nbsp;Thomas A. Brandt,&nbsp;Quinn A. Bumpers,&nbsp;Adam Cook,&nbsp;Mohamed Saad Abdullah Elsayed,&nbsp;Daniel Golec,&nbsp;Nicholas Lewandowski,&nbsp;Phong Nguyen,&nbsp;Robert W. Pipal,&nbsp;Pavel Savechenkov,&nbsp;Christina E. Wong,&nbsp;Eugene Tarlton,&nbsp;John J. Gaudino,&nbsp;Ronald J. Hinklin* and Tony P. Tang,&nbsp;","doi":"10.1021/acs.oprd.4c0044110.1021/acs.oprd.4c00441","DOIUrl":"https://doi.org/10.1021/acs.oprd.4c00441https://doi.org/10.1021/acs.oprd.4c00441","url":null,"abstract":"<p >New synthetic methodologies that access complex saturated building blocks enable the synthesis of drug molecules with unique properties. Here, we report collaborative efforts between Pfizer’s Medicinal Chemistry, Medicinal Chemistry Synthesis Development, and Pharmaceutical Sciences Small Molecule (PSSM) groups for the development of kilogram-scale-enabled synthesis of a type II brain penetrant cMET inhibitor, PF-07907063. The chemistry presented herein demonstrates the importance of implementing a green chemistry approach for developing and applying new transformations throughout the drug development pipeline. Specifically, synthetic planning rooted in the 12 Principles of Green Chemistry led to advancements in deoxygenative photoredox-nickel dual catalysis and cross-electrophile nickel catalysis. The final route significantly lowered the process mass intensity (PMI), increased the yield of the final API, and allowed for the purification of key intermediates through crystallization versus purging impurities via column chromatography, among other improvements.</p>","PeriodicalId":55,"journal":{"name":"Organic Process Research & Development","volume":"29 4","pages":"1048–1057 1048–1057"},"PeriodicalIF":3.1,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143842338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Solvent Eco-Impact Metric: A Tool for Chemists to Drive Sustainability in Chemical Processes across Safety, Health, Waste, and Environmental Aspects 溶剂生态影响指标:化学家在安全、健康、废物和环境方面推动化学过程可持续性的工具
IF 3.1 3区 化学
Organic Process Research & Development Pub Date : 2025-04-07 DOI: 10.1021/acs.oprd.4c0054610.1021/acs.oprd.4c00546
Marco Ferrara*, Federico Della Negra and Massimo Verzini, 
{"title":"Solvent Eco-Impact Metric: A Tool for Chemists to Drive Sustainability in Chemical Processes across Safety, Health, Waste, and Environmental Aspects","authors":"Marco Ferrara*,&nbsp;Federico Della Negra and Massimo Verzini,&nbsp;","doi":"10.1021/acs.oprd.4c0054610.1021/acs.oprd.4c00546","DOIUrl":"https://doi.org/10.1021/acs.oprd.4c00546https://doi.org/10.1021/acs.oprd.4c00546","url":null,"abstract":"<p >The synthesis of active pharmaceutical ingredients (APIs) demands extensive resources, with solvents playing a pivotal role in shaping the safety, health, waste, and environmental impacts of chemical processes. To address the absence of a tailored metric for the requirements of the pharmaceutical industry to rapidly quantify and compare these impacts, we developed a novel tool providing concrete operational guidance to enhance sustainability, cost-effectiveness, and operational efficiency. This metric leverages a comprehensive data set, prioritizes critical impact categories, and evaluates solvent quantities relative to the product output. These features enable it to effectively identify areas of improvement in chemical processes and guide sustainable development initiatives. The experience of the application of the metric by a contract development and manufacturing organization to its processes is presented, demonstrating the effectiveness of the metric for internal benchmarking and establishing sustainability criteria. Furthermore, the metric provided structured, actionable guidelines to support daily process development activities, ultimately serving as a practical tool to achieve corporate environmental, social, and governance (ESG) objectives. While the described benchmarking is not proposed as a general industry standard, the method is adaptable to the unique context and requirements of any chemical or pharmaceutical company. Case studies underscore its capability to pinpoint high-impact solvents, support targeted interventions, and achieve notable reductions in sustainability impacts. Aligned with the United Nations Sustainable Development Goal for responsible production, this metric integrates seamlessly into process evaluation tools, enabling consistent, data-driven improvements. Designed to complement existing methodologies rather than replace them, it enhances chemical process assessments with a rapid, decision-focused approach tailored to the priorities and key impact categories of the pharmaceutical industry. This practical tool fosters sustainability and operational efficiency, addressing critical industry needs.</p>","PeriodicalId":55,"journal":{"name":"Organic Process Research & Development","volume":"29 4","pages":"1110–1124 1110–1124"},"PeriodicalIF":3.1,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acs.oprd.4c00546","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143842354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Solvent Eco-Impact Metric: A Tool for Chemists to Drive Sustainability in Chemical Processes across Safety, Health, Waste, and Environmental Aspects 溶剂生态影响指标:化学家在安全、健康、废物和环境方面推动化学过程可持续性的工具
IF 3.4 3区 化学
Organic Process Research & Development Pub Date : 2025-04-07 DOI: 10.1021/acs.oprd.4c00546
Marco Ferrara, Federico Della Negra, Massimo Verzini
{"title":"Solvent Eco-Impact Metric: A Tool for Chemists to Drive Sustainability in Chemical Processes across Safety, Health, Waste, and Environmental Aspects","authors":"Marco Ferrara, Federico Della Negra, Massimo Verzini","doi":"10.1021/acs.oprd.4c00546","DOIUrl":"https://doi.org/10.1021/acs.oprd.4c00546","url":null,"abstract":"The synthesis of active pharmaceutical ingredients (APIs) demands extensive resources, with solvents playing a pivotal role in shaping the safety, health, waste, and environmental impacts of chemical processes. To address the absence of a tailored metric for the requirements of the pharmaceutical industry to rapidly quantify and compare these impacts, we developed a novel tool providing concrete operational guidance to enhance sustainability, cost-effectiveness, and operational efficiency. This metric leverages a comprehensive data set, prioritizes critical impact categories, and evaluates solvent quantities relative to the product output. These features enable it to effectively identify areas of improvement in chemical processes and guide sustainable development initiatives. The experience of the application of the metric by a contract development and manufacturing organization to its processes is presented, demonstrating the effectiveness of the metric for internal benchmarking and establishing sustainability criteria. Furthermore, the metric provided structured, actionable guidelines to support daily process development activities, ultimately serving as a practical tool to achieve corporate environmental, social, and governance (ESG) objectives. While the described benchmarking is not proposed as a general industry standard, the method is adaptable to the unique context and requirements of any chemical or pharmaceutical company. Case studies underscore its capability to pinpoint high-impact solvents, support targeted interventions, and achieve notable reductions in sustainability impacts. Aligned with the United Nations Sustainable Development Goal for responsible production, this metric integrates seamlessly into process evaluation tools, enabling consistent, data-driven improvements. Designed to complement existing methodologies rather than replace them, it enhances chemical process assessments with a rapid, decision-focused approach tailored to the priorities and key impact categories of the pharmaceutical industry. This practical tool fosters sustainability and operational efficiency, addressing critical industry needs.","PeriodicalId":55,"journal":{"name":"Organic Process Research & Development","volume":"38 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143798412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Process Development toward a Key Fragment of the PCSK9 Inhibitor Enlicitide Decanoate PCSK9抑制剂烯酸酯关键片段的研究进展
IF 3.1 3区 化学
Organic Process Research & Development Pub Date : 2025-04-03 DOI: 10.1021/acs.oprd.4c0050410.1021/acs.oprd.4c00504
Kai-Jiong Xiao*, Yonggang Chen, Yingju Xu, Gao Shang, Lushi Tan, Fangzhou Xie, Chengqian Xiao, Yongpeng Yuan, Baoqiang Wan, Guiquan Liu and Jingjun Yin, 
{"title":"Process Development toward a Key Fragment of the PCSK9 Inhibitor Enlicitide Decanoate","authors":"Kai-Jiong Xiao*,&nbsp;Yonggang Chen,&nbsp;Yingju Xu,&nbsp;Gao Shang,&nbsp;Lushi Tan,&nbsp;Fangzhou Xie,&nbsp;Chengqian Xiao,&nbsp;Yongpeng Yuan,&nbsp;Baoqiang Wan,&nbsp;Guiquan Liu and Jingjun Yin,&nbsp;","doi":"10.1021/acs.oprd.4c0050410.1021/acs.oprd.4c00504","DOIUrl":"https://doi.org/10.1021/acs.oprd.4c00504https://doi.org/10.1021/acs.oprd.4c00504","url":null,"abstract":"<p >Here we report the development of a large-scale manufacturing process for the synthesis of the Northern Fragment of enlicitide decanoate (MK-0616), an orally bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). The key topics covered are (1) process development for the selective tryptophan allylation; (2) development of the one-pot process for two consecutive peptide coupling reactions; (3) process development for the one-pot cleavage of two <i>N</i>-<i>tert</i>-butyloxycarbonyl (<i>N</i>-Boc) groups and a <i>tert</i>-butyl ester; and (4) process development of the magnesium chloride (MgCl<sub>2</sub>)-mediated selective macrolactamization. This optimized process was demonstrated to produce the key fragment at &gt;150 kg scale per batch in the synthesis of enlicitide.</p>","PeriodicalId":55,"journal":{"name":"Organic Process Research & Development","volume":"29 4","pages":"1083–1092 1083–1092"},"PeriodicalIF":3.1,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143842386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Process Development toward a Key Fragment of the PCSK9 Inhibitor Enlicitide Decanoate PCSK9抑制剂烯酸酯关键片段的研究进展
IF 3.4 3区 化学
Organic Process Research & Development Pub Date : 2025-04-03 DOI: 10.1021/acs.oprd.4c00504
Kai-Jiong Xiao, Yonggang Chen, Yingju Xu, Gao Shang, Lushi Tan, Fangzhou Xie, Chengqian Xiao, Yongpeng Yuan, Baoqiang Wan, Guiquan Liu, Jingjun Yin
{"title":"Process Development toward a Key Fragment of the PCSK9 Inhibitor Enlicitide Decanoate","authors":"Kai-Jiong Xiao, Yonggang Chen, Yingju Xu, Gao Shang, Lushi Tan, Fangzhou Xie, Chengqian Xiao, Yongpeng Yuan, Baoqiang Wan, Guiquan Liu, Jingjun Yin","doi":"10.1021/acs.oprd.4c00504","DOIUrl":"https://doi.org/10.1021/acs.oprd.4c00504","url":null,"abstract":"Here we report the development of a large-scale manufacturing process for the synthesis of the Northern Fragment of enlicitide decanoate (MK-0616), an orally bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). The key topics covered are (1) process development for the selective tryptophan allylation; (2) development of the one-pot process for two consecutive peptide coupling reactions; (3) process development for the one-pot cleavage of two <i>N</i>-<i>tert</i>-butyloxycarbonyl (<i>N</i>-Boc) groups and a <i>tert</i>-butyl ester; and (4) process development of the magnesium chloride (MgCl<sub>2</sub>)-mediated selective macrolactamization. This optimized process was demonstrated to produce the key fragment at &gt;150 kg scale per batch in the synthesis of enlicitide.","PeriodicalId":55,"journal":{"name":"Organic Process Research & Development","volume":"41 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143766881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a Scalable Process for an IL-17A Inhibitor LY3509754: Part I: Synthesis of the Pyridazinyl Imidazolidinone Intermediate Enabled by Biocatalysis and CSTR Technologies IL-17A抑制剂LY3509754可扩展工艺的开发:第一部分:生物催化和CSTR技术催化合成吡嗪基咪唑烷酮中间体
IF 3.1 3区 化学
Organic Process Research & Development Pub Date : 2025-04-03 DOI: 10.1021/acs.oprd.5c0000310.1021/acs.oprd.5c00003
Qiang Yang*, Yu Lu, Thomas J. Beauchamp, Kevin P. Cole, Jiang Wang, Srinivas Gangula, Silong Zhang, Zhaoshan Cui, Guopeng Wang, Lei Shi, Dajiang Jing, Fuliang Wei, Xuecheng Jiao, Xiang Li, Na Zhang, Xiangjun Jiang and Yulei Ma, 
{"title":"Development of a Scalable Process for an IL-17A Inhibitor LY3509754: Part I: Synthesis of the Pyridazinyl Imidazolidinone Intermediate Enabled by Biocatalysis and CSTR Technologies","authors":"Qiang Yang*,&nbsp;Yu Lu,&nbsp;Thomas J. Beauchamp,&nbsp;Kevin P. Cole,&nbsp;Jiang Wang,&nbsp;Srinivas Gangula,&nbsp;Silong Zhang,&nbsp;Zhaoshan Cui,&nbsp;Guopeng Wang,&nbsp;Lei Shi,&nbsp;Dajiang Jing,&nbsp;Fuliang Wei,&nbsp;Xuecheng Jiao,&nbsp;Xiang Li,&nbsp;Na Zhang,&nbsp;Xiangjun Jiang and Yulei Ma,&nbsp;","doi":"10.1021/acs.oprd.5c0000310.1021/acs.oprd.5c00003","DOIUrl":"https://doi.org/10.1021/acs.oprd.5c00003https://doi.org/10.1021/acs.oprd.5c00003","url":null,"abstract":"<p >Process development and scale-up of the synthesis of a pyridazinyl imidazolidinone intermediate for the production of an imidazo[1,2-<i>b</i>]pyridazine IL-17A inhibitor are described. A transamination process was developed for the preparation of (<i>S</i>)-3,3,3-trifluoropropane-1,2-diamine, eliminating an unstable enamine intermediate that significantly limited the scalability of the original asymmetric hydrogenation route. A CSTR continuous flow process was developed for the carbonylation of <i>N</i>-(6-chloropyridazin-3-yl)pivalamide under cryogenic conditions that successfully suppressed product decomposition, improving the isolated yield to ∼60% from the ∼40% yield of the batch mode process. A robust KRED process was developed for the reduction of <i>N</i>-(6-chloro-5-(2-methoxyacetyl)pyridazin-3-yl)pivalamide to the corresponding chiral alcohol, which was further derivatized as its triflate for the S<sub>N</sub>2 reaction with (<i>S</i>)-3,3,3-trifluoropropane-1,2-diamine and treated with carbonyl diimidazole to assemble the target pyridazinyl imidazolidinone intermediate. The developed process was successfully scaled up to deliver 157 kg of the pyridazinyl imidazolidinone intermediate to support the production of the final drug substance, demonstrating the robustness of the optimized process.</p>","PeriodicalId":55,"journal":{"name":"Organic Process Research & Development","volume":"29 4","pages":"986–1005 986–1005"},"PeriodicalIF":3.1,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143842177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a Scalable Process for an IL-17A Inhibitor LY3509754: Part I: Synthesis of the Pyridazinyl Imidazolidinone Intermediate Enabled by Biocatalysis and CSTR Technologies IL-17A抑制剂LY3509754可扩展工艺的开发:第一部分:生物催化和CSTR技术催化合成吡嗪基咪唑烷酮中间体
IF 3.4 3区 化学
Organic Process Research & Development Pub Date : 2025-04-03 DOI: 10.1021/acs.oprd.5c00003
Qiang Yang, Yu Lu, Thomas J. Beauchamp, Kevin P. Cole, Jiang Wang, Srinivas Gangula, Silong Zhang, Zhaoshan Cui, Guopeng Wang, Lei Shi, Dajiang Jing, Fuliang Wei, Xuecheng Jiao, Xiang Li, Na Zhang, Xiangjun Jiang, Yulei Ma
{"title":"Development of a Scalable Process for an IL-17A Inhibitor LY3509754: Part I: Synthesis of the Pyridazinyl Imidazolidinone Intermediate Enabled by Biocatalysis and CSTR Technologies","authors":"Qiang Yang, Yu Lu, Thomas J. Beauchamp, Kevin P. Cole, Jiang Wang, Srinivas Gangula, Silong Zhang, Zhaoshan Cui, Guopeng Wang, Lei Shi, Dajiang Jing, Fuliang Wei, Xuecheng Jiao, Xiang Li, Na Zhang, Xiangjun Jiang, Yulei Ma","doi":"10.1021/acs.oprd.5c00003","DOIUrl":"https://doi.org/10.1021/acs.oprd.5c00003","url":null,"abstract":"Process development and scale-up of the synthesis of a pyridazinyl imidazolidinone intermediate for the production of an imidazo[1,2-<i>b</i>]pyridazine IL-17A inhibitor are described. A transamination process was developed for the preparation of (<i>S</i>)-3,3,3-trifluoropropane-1,2-diamine, eliminating an unstable enamine intermediate that significantly limited the scalability of the original asymmetric hydrogenation route. A CSTR continuous flow process was developed for the carbonylation of <i>N</i>-(6-chloropyridazin-3-yl)pivalamide under cryogenic conditions that successfully suppressed product decomposition, improving the isolated yield to ∼60% from the ∼40% yield of the batch mode process. A robust KRED process was developed for the reduction of <i>N</i>-(6-chloro-5-(2-methoxyacetyl)pyridazin-3-yl)pivalamide to the corresponding chiral alcohol, which was further derivatized as its triflate for the S<sub>N</sub>2 reaction with (<i>S</i>)-3,3,3-trifluoropropane-1,2-diamine and treated with carbonyl diimidazole to assemble the target pyridazinyl imidazolidinone intermediate. The developed process was successfully scaled up to deliver 157 kg of the pyridazinyl imidazolidinone intermediate to support the production of the final drug substance, demonstrating the robustness of the optimized process.","PeriodicalId":55,"journal":{"name":"Organic Process Research & Development","volume":"35 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a Scalable Process for an IL-17A Inhibitor LY3509754: Part III. Assembly of Drug Substance, Salt Formation, and Impurity Control IL-17A抑制剂LY3509754可扩展工艺的开发:第三部分。原料药的组装、盐的形成和杂质控制
IF 3.4 3区 化学
Organic Process Research & Development Pub Date : 2025-04-02 DOI: 10.1021/acs.oprd.5c00005
Qiang Yang, Ryan J. Linder, Yu Lu, Thomas J. Beauchamp, Timothy A. Woods, David A. Coates, Brandon J. Reizman, Jonas Y. Buser, Michael E. Laurila, Nicholas A. Magnus, Yongjie Yu, Lili Han, Ping Huang
{"title":"Development of a Scalable Process for an IL-17A Inhibitor LY3509754: Part III. Assembly of Drug Substance, Salt Formation, and Impurity Control","authors":"Qiang Yang, Ryan J. Linder, Yu Lu, Thomas J. Beauchamp, Timothy A. Woods, David A. Coates, Brandon J. Reizman, Jonas Y. Buser, Michael E. Laurila, Nicholas A. Magnus, Yongjie Yu, Lili Han, Ping Huang","doi":"10.1021/acs.oprd.5c00005","DOIUrl":"https://doi.org/10.1021/acs.oprd.5c00005","url":null,"abstract":"A 5-step cGMP sequence for the preparation of an IL-17A inhibitor <b>1</b> was optimized and scaled up to deliver a total of 66 kg of the final drug substance <b>1</b> to support clinical and product development studies. Salt formation and polymorph screening identified a suitable polymorph of the hemiedisylate salt that provided desirable physical properties. Key impurities in the final drug substance were identified, and control strategies were developed and executed to control them to acceptable levels in the production batches.","PeriodicalId":55,"journal":{"name":"Organic Process Research & Development","volume":"73 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143758663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a Scalable Process for an IL-17A Inhibitor LY3509754: Part III. Assembly of Drug Substance, Salt Formation, and Impurity Control IL-17A抑制剂LY3509754可扩展工艺的开发:第三部分。原料药的组装、盐的形成和杂质控制
IF 3.1 3区 化学
Organic Process Research & Development Pub Date : 2025-04-02 DOI: 10.1021/acs.oprd.5c0000510.1021/acs.oprd.5c00005
Qiang Yang*, Ryan J. Linder, Yu Lu, Thomas J. Beauchamp, Timothy A. Woods, David A. Coates, Brandon J. Reizman, Jonas Y. Buser, Michael E. Laurila, Nicholas A. Magnus, Yongjie Yu, Lili Han and Ping Huang, 
{"title":"Development of a Scalable Process for an IL-17A Inhibitor LY3509754: Part III. Assembly of Drug Substance, Salt Formation, and Impurity Control","authors":"Qiang Yang*,&nbsp;Ryan J. Linder,&nbsp;Yu Lu,&nbsp;Thomas J. Beauchamp,&nbsp;Timothy A. Woods,&nbsp;David A. Coates,&nbsp;Brandon J. Reizman,&nbsp;Jonas Y. Buser,&nbsp;Michael E. Laurila,&nbsp;Nicholas A. Magnus,&nbsp;Yongjie Yu,&nbsp;Lili Han and Ping Huang,&nbsp;","doi":"10.1021/acs.oprd.5c0000510.1021/acs.oprd.5c00005","DOIUrl":"https://doi.org/10.1021/acs.oprd.5c00005https://doi.org/10.1021/acs.oprd.5c00005","url":null,"abstract":"<p >A 5-step cGMP sequence for the preparation of an IL-17A inhibitor <b>1</b> was optimized and scaled up to deliver a total of 66 kg of the final drug substance <b>1</b> to support clinical and product development studies. Salt formation and polymorph screening identified a suitable polymorph of the hemiedisylate salt that provided desirable physical properties. Key impurities in the final drug substance were identified, and control strategies were developed and executed to control them to acceptable levels in the production batches.</p>","PeriodicalId":55,"journal":{"name":"Organic Process Research & Development","volume":"29 4","pages":"1019–1035 1019–1035"},"PeriodicalIF":3.1,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143842383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信